Login to Your Account



Platform party: Resurging interest spurs more deals, but terms call for caution

By Randy Osborne
Staff Writer

Thursday, June 9, 2016

SAN FRANCISCO – "Platforms are 'in' again," said Arthur Sands, CEO of Nurix Inc., which last September bagged an agreement with Celgene Corp. that brought $150 million up front plus an undisclosed equity investment to discover and develop drugs that target the ubiquitin proteasome system (UPS).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription